by Joseph Kamgno, Sébastien D. Pion, Cédric B. Chesnais et al.
N Engl J Med 2017; 377:2044-2052, November 23, 2017
9 pp. 441 kB
Implementation of an ivermectin-based community treatment strategy for the elimination of onchocerciasis or lymphatic filariasis has been delayed in Central Africa because of the occurrence of serious adverse events, including death, in persons with high levels of circulating Loa loa microfilariae. The LoaScope, a field-friendly diagnostic tool to quantify L. loa microfilariae in peripheral blood, enables rapid, point-of-care identification of persons at risk for serious adverse events.